# A Study in Second Line Metastatic Colorectal Cancer

> **NCT01183780** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1072 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Ramucirumab
- **BIOLOGICAL:** Placebo
- **DRUG:** Irinotecan
- **DRUG:** Folinic Acid
- **DRUG:** 5-Fluorouracil

## Key facts

- **NCT ID:** NCT01183780
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-02
- **Primary completion:** 2014-07-17
- **Final completion:** 2016-06-20
- **Target enrollment:** 1072 (ACTUAL)
- **Last updated:** 2019-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01183780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01183780, "A Study in Second Line Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01183780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*